Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12
Jessica C Amlin-Van Schaick1, Sungjin Kim, Christina DiFabio
1Mouse Cancer Genetics Program, National Cancer Institute, West 7th St at Fort Detrick, Frederick, MD 21702, USA.
Abstract:
While many cancers show a sex bias, the genetic basis and molecular mechanisms underlying sex bias are not always clear. Astrocytoma and glioblastoma show male predominance in humans. We have shown previously that glial tumors forming in the Nf1-/+; Trp53-/+cis (NPcis) mouse model also show a sex bias in some genetic contexts. Using cross-species comparisons we have identified candidate male-specific modifiers of astrocytoma/glioblastoma. Linkage analysis of B6X(B6X129)-NPcis mice identifies a modifier of astrocytoma resistance specific to males, named Arlm1, on distal mouse Chr 12. Arlm1 is syntenic to human Chr 7p15, 7p21, 7q36, and 14q32 regions that are altered in human glioblastoma. A subset of these genes shows male-specific correlations to glioblastoma patient survival time and represents strong candidates for the Arlm1 modifier gene. Identification of male-specific modifier genes will lead to a better understanding of the molecular basis of male predominance in astrocytoma and glioblastoma.
Insights
Researchers identified a male-specific gene modifier, Arlm1, influencing astrocytoma resistance in mice. This discovery sheds light on the genetic basis of male predominance in brain tumors like glioblastoma.
Area of Science:
- Neuro-oncology
- Cancer Genetics
- Comparative Genomics
Background:
- Astrocytoma and glioblastoma exhibit a male predominance in human populations.
- The genetic underpinnings and molecular mechanisms driving this sex bias remain incompletely understood.
- Previous studies in the Nf1-/+; Trp53-/+cis (NPcis) mouse model indicated sex-biased glial tumor formation in specific genetic contexts.
Purpose of the Study:
- To identify candidate male-specific genetic modifiers contributing to astrocytoma and glioblastoma development.
- To investigate the molecular basis of male predominance in these brain tumors.
- To explore potential therapeutic targets based on sex-specific genetic factors.
Main Methods:
- Cross-species comparative genomics to identify potential modifiers.
- Linkage analysis in B6X(B6X129)-NPcis mice to locate modifier genes.
- Synteny analysis to correlate mouse chromosomal regions with human glioblastoma-associated genomic alterations.
- Correlation analysis between candidate genes and glioblastoma patient survival data.
Main Results:
- A novel male-specific modifier of astrocytoma resistance, designated Arlm1, was identified on distal mouse Chromosome 12.
- Arlm1 is syntenic to human chromosomal regions (7p15, 7p21, 7q36, 14q32) frequently altered in human glioblastoma.
- A subset of genes within these syntenic regions demonstrated male-specific correlations with glioblastoma patient survival, implicating them as strong candidates for Arlm1.
Conclusions:
- The identification of Arlm1 provides a key genetic factor contributing to sex bias in astrocytoma and glioblastoma.
- Understanding male-specific modifiers like Arlm1 is crucial for elucidating the molecular mechanisms behind male predominance in these cancers.
- These findings pave the way for sex-specific therapeutic strategies in neuro-oncology.
More Related Videos
05:40AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
Published on: November 29, 2024
06:47In Utero Electroporation of Multiaddressable Genome-Integrating Color (MAGIC) Markers to Individualize Cortical Mouse Astrocytes
Published on: May 21, 2020
